Campbell & Co Investment Adviser’s Niagen Bioscience NAGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$205K Sell
64,256
-14,101
-18% -$57.2K 0.01% 974
2026
Q1
$346K Buy
+78,357
New +$423K 0.02% 850
2025
Q3
Sell
-104,431
Closed -$1.5M 1434
2025
Q2
$1.5M Buy
+104,431
New +$1.03M 0.09% 338
2022
Q1
Sell
-10,100
Closed -$38K 939
2021
Q4
$38K Buy
+10,100
New +$54.5K 0.01% 593
2020
Q4
Sell
-12,000
Closed -$48K 591
2020
Q3
$48K Buy
+12,000
New +$57.9K 0.04% 368

Other funds holding NAGE

Campbell & Co Investment Adviser's NAGE Position: Q2 2026 in Review

Campbell & Co Investment Adviser reduced its Niagen Bioscience (NAGE) stake by 18% in Q2 2026, selling an estimated $57.2K and leaving 64,256 shares worth $205K. The position accounts for 0.01% of the portfolio, ranked #974.

Campbell & Co Investment Adviser first reported a position in NAGE in Q3 2020 and has held it in 5 quarters since. The position peaked at $1.5M in Q2 2025. 28 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • Campbell & Co Investment Adviser held 64,256 shares of Niagen Bioscience worth $205K as of Q2 2026.
  • Campbell & Co Investment Adviser sold 14,101 Niagen Bioscience shares in Q2 2026, an estimated $57.2K.
  • Niagen Bioscience made up 0.01% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #974 holding.
  • Campbell & Co Investment Adviser first reported a position in Niagen Bioscience in Q3 2020 and has held it in 5 quarters since.
  • Campbell & Co Investment Adviser's Niagen Bioscience position peaked at $1.5M in Q2 2025.
  • 28 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.